pharma · Chronic Spontaneous Urticaria · Asthma
Novartis India
Novartis Pharmaceuticals
Novartis Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Spontaneous Urticaria, Asthma, Systemic Lupus Erythematosus, Breast Cancer, Multiple Sclerosis. NovaP
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Mumbai, IN
- Founded
- 1996
- Employees
- 2,240
- Programs
- 341
- Drugs
- 317
- Patents
- 0
CBYL719X2402
Phase 2 · small molecule · Adult patients with PIK3CA mutant, HR-positive, HER2-negative advanced breast cancer
CBYL719X2402 for Adult patients with PIK3CA mutant, HR-positive, HER2-negative advanced breast cancer is a Phase 2 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code CBYL719X2402
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Adult patients with PIK3CA mutant, HR-positive, HER2-negative advanced breast cancer
- Status
- active
- Trials
- 1